Janssen Claims Preemption In $4M Topamax Defect Appeal
By Matt Fair ( April 23, 2014, 6:40 PM EDT) -- Janssen Pharmaceuticals Inc. urged a Pennsylvania appeals court Monday to overturn a $4 million jury verdict on the grounds that federal preemption barred state-law claims that the company failed to warn consumers about the risk of birth defects associated with its Topamax epilepsy drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.